Loading organizations...
§ Private Profile · San Francisco, CA, USA
Biopharmaceutical company developing oral small-molecule drugs targeting RNA for neurology, oncology, and rare genetic disorders.
Arrakis Therapeutics is a Waltham, Massachusetts-based biopharmaceutical company that develops oral small-molecule drugs targeting RNA to treat neurology, oncology, and rare genetic disorders. The organization utilizes proprietary platforms, specifically TRYST and PEARL-seq, to identify disease-relevant RNA targets and rationally design anti-RNA drug candidates for previously intractable challenges in drug discovery. The enterprise generates revenue through strategic research and development collaborations, securing a $190 million licensing agreement with Roche in April 2020 and a $75 million upfront payment from an Amgen partnership in January 2022. Arrakis Therapeutics has also raised significant venture capital, including a $38 million Series A in 2017 and a $75 million Series B in 2019, with financial backing from prominent investors such as Canaan Partners, Celgene, and Pfizer. The company was founded in 2015 by Jennifer Petter and Russell C. Petter.
Arrakis has raised $38.0M across 1 funding round.
Arrakis has raised $38.0M in total across 1 funding round.
Arrakis has raised $38.0M across 1 funding round. Most recently, it raised $38.0M Series A in February 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 27, 2017 | $38M Series A | Canaan Partners | Henri Termeer, Advent Life Sciences, Celgene, Osage University Partners, Pfizer | Announced |
Arrakis has raised $38.0M in total across 1 funding round.
Arrakis's investors include Canaan Partners, Henri Termeer, Advent Life Sciences, Celgene, Osage University Partners, Pfizer.